NO.1 PHARMACY(SH:600833)2026-01-16 10:00Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 41.5 million and 62 million yuan, representing a decrease of 10.10613 million to 12.15613 million yuan compared to the previous year, a year-on-year decline of 61.98% to 74.55%[4] - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between 4.9 million and 7.3 million yuan, with a potential decrease of 197.4 thousand yuan to an increase of 42.6 thousand yuan compared to the previous year, reflecting a year-on-year change of -28.72% to +6.20%[4] - In the previous year, the company achieved a total profit of 216.2713 million yuan and a net profit attributable to shareholders of the parent company of 163.0613 million yuan[6] - The decrease in net profit is primarily attributed to the presence of housing expropriation compensation in the previous year's results[7] - The earnings per share for the previous year was 0.73 yuan[6] Earnings Forecast Details - The earnings forecast is based on preliminary calculations by the company's finance department and has not been audited by a registered accountant[8] - The company emphasizes that there are no significant uncertainties affecting the accuracy of this earnings forecast[8] - Investors are advised to make cautious decisions and be aware of investment risks[4] - The data provided in the earnings forecast is preliminary and the final financial data will be disclosed in the company's official 2025 annual report[9] - The earnings forecast period is from January 1, 2025, to December 31, 2025[4]